Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonucleoside-diphosphate reductase large subunit (RRM1) is the catalytic and regulatory subunit of ribonucleotide reductase (RNR), a key enzyme that catalyzes the rate-limiting conversion of ribonucleoside diphosphates (NDPs) to deoxyribonucleoside diphosphates (dNDPs). This process is essential for maintaining balanced deoxyribonucleotide (dNTP) pools required for de novo DNA replication and repair. RRM1 contains a catalytic site (C-site) and two distinct allosteric regulatory sites: the activity site (A-site), which controls overall enzyme activity, and the specificity site (S-site), which regulates substrate preference. Binding of ATP to the A-site activates the enzyme, whereas binding of dATP or certain nucleoside analog triphosphates (such as clofarabine triphosphate) induces the formation of inactive RRM1 hexamers, shutting down dNTP synthesis. Overexpression of RRM1 is strongly associated with resistance to nucleoside analog chemotherapies like gemcitabine, making its expression levels a critical predictive biomarker in various cancers, including non-small cell lung cancer and pancreatic cancer. Consequently, targeting the RRM1 allosteric site with small molecules or nucleoside analogs represents a powerful therapeutic strategy to deplete dNTP pools, disrupt DNA replication, and induce apoptosis in rapidly proliferating cancer cells.
Allosteric inhibition of ribonucleotide reductase by binding to the activity site (A-site) or specificity site (S-site) of the RRM1 subunit. This binding induces inactive hexamerization of the enzyme, depleting intracellular deoxyribonucleotide (dNTP) pools and halting DNA replication and repair.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleoside-diphosphate reductase large subunit (RRM1).